Tango Therapeutics, Inc. (TNGX)

Tango Therapeutics, Inc. is trading at $22.72, up 0.84% on the session. The 50 day average sits at $23.60 and the 200 day at $22.33, which puts the stock in a uptrend. RSI is at 46.7, which reads as neutral, and MACD is bearish crossover. Volume is above average.

The nearest support is around $21.64 with resistance near $24.47, so that band frames the current range. Average daily movement is roughly $1.80, or about 7.9% of the share price, which is what any stop placement has to allow for. The overall health score of 41 out of 100 combines a trend score of 53, momentum of 36 and a risk score of 30.

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.